1865results about "Amine active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Provided herein are SOS1 protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an SOS1-mediated disorder, disease, or condition.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.

The invention discloses a novel application of a small molecule compound BRD4780 in resisting ricin, the small molecule compound BRD4780 has a remarkable effect of resisting ricin toxicity and can be used in development of anti-ricin drugs, a brand new candidate molecule is provided for development of the anti-ricin drugs, the drug research and development blank in the field is filled, and the application of the small molecule compound BRD4780 in resisting ricin is developed. The method has important significance in the aspects of clinical treatment, biological protection and immunotoxin treatment safety optimization, and is wide in application prospect.

Hydrogen-bonded framework nanoparticles comprising a chemiluminescent compound (e.g., L-012) are provided and can be used, e.g., for sono-optogenetic treatment of neurodegenerative diseases such as Parkinson's disease. Related in vivo and therapeutic methods are also provided.

Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the sequence of SEQ ID NO: 35, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

It relates to aldoximes or pharmaceutically acceptable salts thereof or isomers thereof able of releasing nitric oxide (NO) for use in the treatment of a condition or a disease which is sensible to the action of the NO, wherein the treatment comprises administering the aldoxime to a subject and releasing NO from the aldoxime through an in vivo enzymatically catalyzed redox reaction at physiological pH, as well as to the in vivo use of such aldoximes or acceptable salts for plants thereof or isomers thereof for biological applications which are sensible to the action of the NO in plants, wherein the biological application is selected from the group consisting of plant rooting agent, plant structure modifier, stimulators of the tolerance to abiotic or biotic stress, plant protector from stress induced by ammonium nutrition as an exclusive source of nitrogen, plants protector from hydric stress, and as germination inducer. It also relates to compositions comprising them.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral instant film with high drug loading capacity. The oral instant film agent comprises the following components: an active component, a film-forming material, a plasticizer, a coloring agent and a flavoring agent. The film-forming material is preferably combined with hydroxypropyl methylcellulose E15 and xanthan gum, so that the high drug loading capacity of the oral cavity instant film agent is ensured. Film-forming materials including hydroxypropyl methylcellulose E15 and xanthan gum are combined and compounded with a plasticizer polyethylene glycol 400, and sucralose is adopted as a flavoring agent, so that the stability of the oral instant film agent is ensured. The oral cavity instant film is good in appearance property, moderate in flexibility, good in taste, high in drug loading capacity, good in stability, low in cost, easy to operate, free of heating and suitable for industrial production.

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders. Provided herein are also treatment methods using the pharmaceutical compounds, pharmaceutical compositions, and pharmaceutically acceptable salts of the present disclosure.

Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion: cation molar ratio of from about 1:1 to about 1:3, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

According to the compound quaternary ammonium salt disinfectant for the sterile environment and the preparation method thereof, the benzalkonium chloride, the polyhexamethylene biguanide hydrochloride and the plant polysaccharide are compounded to form the positively charged plant polysaccharide compound disinfectant under the action of the sodium sulfite or the potassium sulfite by utilizing a compound synergistic principle, so that the compound quaternary ammonium salt disinfectant for the sterile environment is obtained. Positive charges are promoted to penetrate through cell walls of bacterial biofilms, so that an excellent bactericidal effect is achieved; the sodium hyaluronate, the enhancer and the glycerol are cooperatively used, so that sodium ions are combined with dehydrogenation groups in polysaccharide and hydroxyl groups, carboxyl groups and the like of other components to form a relatively stable internal net-shaped structure, and the situation that quaternary ammonium salt reacts with metal ions in the environment to reduce the disinfection effect is effectively avoided; meanwhile, the sodium hyaluronate and the glycerol are used for enhancing the compatibility of all the components, and the moisturizing effect of the components is fully utilized, so that the hand sanitizer is not only suitable for disinfection of object surfaces and space environments in a sterile environment, but also can be used for disinfection of hands of a human body.

The invention belongs to the technical field of medicines, and particularly relates to a composition for improving obesity and promoting cardiovascular health as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 5 to 20 parts of glycine betaine, 1 to 5.5 parts of choline chloride, 0.5 to 4 parts of L-theanine, 1 to 15 parts of alpha-ketoglutarate calcium, 0.5 to 3 parts of black ginger extract, 0.05 to 0.25 part of black pepper extract, 0.5 to 3 parts of ginkgo leaf extract and 1 to 6 parts of black garlic juice powder. According to the invention, the eight components are selected and are scientifically combined in an optimal quantity ratio range, and the prepared composition can better reduce the inflammation level of a body, regulate abnormal blood fat, improve the lipid metabolism disorder state and effectively reduce impulsive diet behaviors, so that comprehensive improvement of obesity and cardiovascular related risks is realized, and the health-care effect of a human body is improved. The body is effectively assisted to maintain metabolic health.

The invention belongs to the technical field of drug delivery systems, and discloses a two-dimensional vermiculite-based drug delivery system and a preparation method and application thereof. The preparation method comprises the following steps: carrying out ion exchange on expanded vermiculite, NaCl and LiCl, stripping by using a mechanical stripping sheet, centrifuging to obtain a two-dimensional vermiculite nanosheet dispersion liquid, dispersing a drug in the two-dimensional vermiculite nanosheet dispersion liquid, and forming a film to obtain the two-dimensional vermiculite-based drug delivery unit. The drug is synergistically loaded between layers and on the surface of the vermiculite; rich hydroxyl groups and interlayer cations on the end surface of the vermiculite interact with the drug, so that the drug release time is relatively long; the vermiculite-based drug delivery system can realize gradient order release of drugs according to a sequence from the surface to the interlayer through pH response of an affected part. Meanwhile, the vermiculite-based drug delivery system provides an antibacterial effect through enzyme-like catalytic activity, and avoids the problems of abuse of antibiotics and drug resistance.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

The disclosure relates to macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the macrocyclic compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

A pharmaceutical composition comprising a metal channel activator and a glutamic acid modulator is provided. Also provided is a method of treating depressive disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a neurological or neurodegenerative disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a pain disorder comprising administering the pharmaceutical composition.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

Compositions and methods for treating viral infections include conjugates containing an Fc monomer, an Fc domain, and a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc-binding peptide, albumin protein, or albumin-binding peptide. In particular, the conjugates can be used to treat viral infections, such as influenza virus infections.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.